comparemela.com

Latest Breaking News On - Spikimm - Page 1 : comparemela.com

SpikImm, a Biotechnology Company Founded by Truffle Capital Under License from the Institut Pasteur, Announces that the Clinical Trials for SPK001, its Monoclonal Antibody Against SARS-COV-2, Have Begun

This Clinical Trial Has Been Awarded National Priority Research Status by the French Government SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company

United statesArmand rigaudyAntoine pauInstitut pasteurPhilippe poulettyHugo mouquetPrimatice conseilKarine lacombeResearch unitNational steering committee for therapeutic trialsHugo mouquet inserm joint research unitXencor incUniversity professorInstitut pasteur human immunology laboratoryTruffle capitalHuman immunology laboratory

SpikImm, a Biotech Company Founded by Truffle Capital and Institut Pasteur, Announces That Its Monoclonal Antibody Neutralises All SARS-COV-2 Variants of Concern, Including Omicron (BA 1 and BA 2)

Results are available as preprint and have been submitted in an international peer-reviewed journal. https://www.biorxiv.org/content/10.1101/2022.04.01.486719v1 SpikImm expects to initiate

France generalInstitut pasteur insermInstitut pasteurPhilippe poulettyHugo mouquetPatrick kronArmand rigaudyBernard louis roquesAntoine pauLouis pasteurPrimatice conseilInstitut pasteur international networkLife sciences medtechHumoral immunologyEmergency use authorizationScientific director

vimarsana © 2020. All Rights Reserved.